<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharm Res</journal-id><journal-id journal-id-type="iso-abbrev">Pharm. Res</journal-id><journal-title-group><journal-title>Pharmaceutical Research</journal-title></journal-title-group><issn pub-type="ppub">0724-8741</issn><issn pub-type="epub">1573-904X</issn><publisher><publisher-name>Springer US</publisher-name><publisher-loc>New York</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7247743</article-id><article-id pub-id-type="publisher-id">2842</article-id><article-id pub-id-type="doi">10.1007/s11095-020-02842-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Perspective</subject></subj-group></article-categories><title-group><article-title>Repurposing Quaternary Ammonium Compounds as Potential Treatments for COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Baker</surname><given-names>Nancy</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Antony J.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tropsha</surname><given-names>Alexander</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-5691-5790</contrib-id><name><surname>Ekins</surname><given-names>Sean</given-names></name><address><email>sean@collaborationspharma.com</email></address><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.419407.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 4665 8158</institution-id><institution>Leidos, Research Triangle Park, </institution></institution-wrap>Durham, North Carolina USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.418698.a</institution-id><institution-id institution-id-type="ISNI">0000 0001 2146 2763</institution-id><institution>Center for Computational Toxicology and Exposure, Office of Research and Development, </institution><institution>U.S. Environmental Protection Agency (U.S. EPA), Research Triangle Park, </institution></institution-wrap>Durham, North Carolina USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>Laboratory for Molecular Modeling, </institution><institution>UNC Eshelman School of Pharmacy, UNC Chapel Hill, </institution></institution-wrap>Chapel Hill, North Carolina 27599 USA </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.492575.8</institution-id><institution>Collaborations Pharmaceuticals, Inc., </institution></institution-wrap>840 Main Campus Drive, Lab 3510, Raleigh, North Carolina 27606 USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.10698.36</institution-id><institution-id institution-id-type="ISNI">0000000122483208</institution-id><institution>UNC Catalyst for Rare Diseases, </institution><institution>Eshelman School of Pharmacy, UNC Chapel Hill, </institution></institution-wrap>Chapel Hill, North Carolina 27599 USA </aff></contrib-group><pub-date pub-type="epub"><day>25</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="ppub"><year>2020</year></pub-date><volume>37</volume><issue>6</issue><elocation-id>104</elocation-id><history><date date-type="received"><day>6</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>18</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">The COVID-19 pandemic has highlighted an important role for drug repurposing. Quaternary ammonium compounds such as ammonium chloride, cetylpyridinium and miramistin represent widely accessible antiseptic molecules with well-known broad-spectrum antiviral activities and represent a repurposing opportunity as therapeutics against SARS-CoV-2.</p><sec><title>Electronic supplementary material</title><p>The online version of this article (10.1007/s11095-020-02842-8) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Key words</title><kwd>ammonium chloride</kwd><kwd>antiseptic</kwd><kwd>cetylpyridinium chloride</kwd><kwd>SARS-CoV-2</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000057</institution-id><institution>National Institute of General Medical Sciences</institution></institution-wrap></funding-source><award-id>R44GM122196-02A1</award-id><principal-award-recipient><name><surname>Ekins</surname><given-names>Sean</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006108</institution-id><institution>National Center for Advancing Translational Sciences</institution></institution-wrap></funding-source><award-id>R21TR001718</award-id><principal-award-recipient><name><surname>Ekins</surname><given-names>Sean</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>1OT2TR002514-01</award-id><principal-award-recipient><name><surname>Tropsha</surname><given-names>Alexander</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Science+Business Media, LLC, part of Springer Nature 2020</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">The coronavirus family recently gained a new member in SARS-CoV-2 to go along with SARS-CoV and MERS-CoV. Infection with SARS-CoV-2 causes COVID-19 which has rapidly become a pandemic (with at the time of writing millions infected and hundreds of thousands dead) requiring social distancing, leading to global shutdowns, resulting in a recession, and pushing healthcare infrastructures to the breaking point. This pandemic is demanding an urgent response and we need to rapidly find treatments which can be accomplished by using existing drugs. Thus, drug repurposing for COVID-19 has garnered mainstream attention which did not occur in previous epidemics (<xref ref-type="bibr" rid="CR1">1</xref>).</p><p id="Par3">Initially the response from China and elsewhere was for scientists to look at compounds tested previously against SARS and MERS almost exclusively (<xref ref-type="bibr" rid="CR2">2</xref>). Ritonavir/lopinavir, remdesivir (repurposed from Ebola and FDA emergency approved), chloroquine and hydroxychloroquine (both now FDA emergency approved, see Supplementary Material) are the most well-known compounds currently in clinical trials. Other drug repurposing efforts have used computational approaches such as docking or biological network mining to identify molecules as candidates for future testing (<xref ref-type="bibr" rid="CR2">2</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>) (Supplementary Material). To date there have been few large-scale high-throughput repurposing screens of antiviral inhibition described in the literature (<xref ref-type="bibr" rid="CR8">8</xref>). These data as well as the earlier SARS and MERS data (<xref ref-type="bibr" rid="CR9">9</xref>,<xref ref-type="bibr" rid="CR10">10</xref>) could ultimately be useful for machine learning models in order to predict new molecules from a much wider array of sources and select compounds to test <italic>in vitro</italic> and <italic>in vivo</italic>. However, there are only a small number of compounds to date (~100) with reported reliable <italic>in vitro</italic> data.</p><sec id="Sec2"><title>Bibliometric Analysis Leads to Quaternary Ammonium Compounds</title><p id="Par4">An exhaustive bibliometric analysis of drug repurposing over the decades conducted by this team recently has described the many drugs that have been tested for other indications (<xref ref-type="bibr" rid="CR11">11</xref>). This analysis highlighted chloroquine as one of the most repurposed approved drugs which has been tested against hundreds of diseases (<xref ref-type="bibr" rid="CR11">11</xref>). Not surprisingly, chloroquine has also been identified by several groups (in China, South Korea and the USA, (<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>) to have micromolar activity against SARS-CoV-2 <italic>in vitro</italic> and along with the derivative hydroxychloroquine has even entered multiple clinical trials (Supplementary Material). The results have not suggested good efficacy as yet (<xref ref-type="bibr" rid="CR12">12</xref>) from the limited clinical trial reports. This could be due to a number of reasons such as the metabolism and disposition of these drugs and the therapeutic window. We have now used the same text mining approach to focus solely on drugs that have been used in the treatment of coronaviruses (Supplementary Material, Table S<xref rid="MOESM1" ref-type="media">1</xref>). This analysis identified ammonium chloride, which is commonly used as a treatment option for severe cases of <ext-link ext-link-type="uri" xlink:href="https://www.rxlist.com/script/main/art.asp?articlekey=18074">metabolic</ext-link><ext-link ext-link-type="uri" xlink:href="https://www.rxlist.com/script/main/art.asp?articlekey=6852">alkalosis</ext-link>, as a drug of interest. Ammonium chloride is a quaternary ammonium compound that is known to also have antiviral activity (<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>) against coronavirus (Supplementary Material) and has a mechanism of action such as raising the endocytic and lysosomal pH, which it shares with chloroquine (<xref ref-type="bibr" rid="CR15">15</xref>). Review of the text-mined literature also indicated a high-frequency of quaternary ammonium disinfectants as treatments for many viruses (<xref rid="MOESM1" ref-type="media">Supplementary Material</xref>) (<xref ref-type="bibr" rid="CR16">16</xref>,<xref ref-type="bibr" rid="CR17">17</xref>), including coronaviruses: these act by deactivating the protective lipid coating that enveloped viruses like SARS-CoV-2 rely on. Quaternary ammonium compounds are widely recommended to kill viruses and there are over 350 products on EPA&#x02019;s List N: Disinfectants for use against SARS-CoV-2 (<xref rid="MOESM1" ref-type="media">Supplementary Material</xref>. The disinfectant concentrations and contact times (associated with multiple viruses) for many of the disinfecting chemicals on the EPA list have been reported and&#x02009;&#x0003e;&#x02009;140 can deactivate the virus in just a few minutes (<xref ref-type="bibr" rid="CR18">18</xref>).</p></sec><sec id="Sec3"><title>Cetylpyridinium Chloride and Miramistin</title><p id="Par5">This information led us on a larger search for quaternary ammonium compounds with activity against coronaviruses and possible identification of chemicals that have already been tested in the clinic and could be used as a potential treatment for COVID-19 (Table S<xref rid="MOESM1" ref-type="media">2</xref>). One of the disinfectants that has been shown to be destructive to viruses (Supplementary Material) and widely used in personal care products is cetylpyridinium chloride (Table <xref rid="Tab1" ref-type="table">1</xref>) (<xref ref-type="bibr" rid="CR19">19</xref>,<xref ref-type="bibr" rid="CR20">20</xref>). This compound is found predominantly in mouthwashes and is listed by the FDA as Generally Regarded as Safe (GRAS) such that it is also being used as an antimicrobial agent for meat and poultry products (up to 1%). Cetylpyridinium chloride has been used in multiple clinical trials (<xref ref-type="bibr" rid="CR21">21</xref>), including as a treatment against respiratory infections (<xref ref-type="bibr" rid="CR21">21</xref>) validating its use as an antiviral. Cetylpyridinium likely promotes virus inactivation by destroying the capsid as well as through its lysosomotropic action, which, as discussed above, is common for quaternary ammonium compounds. This raises the question as to whether some of the drugs identified with antiviral activity against SARS-CoV-2 <italic>in vitro</italic> behave similarly, namely they may destroy the virus capsid as well as accumulating in the lysosome or endosomes and ultimately blocking viral entry. Additional published studies have suggested that this effect can be attenuated by the use of Cathepsin-L inhibitors (<xref ref-type="bibr" rid="CR22">22</xref>). Another potential treatment candidate is miramistin (Table <xref rid="Tab1" ref-type="table">1</xref>), a <ext-link ext-link-type="uri" xlink:href="https://ru.wikipedia.org/wiki/%D0%9B%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2%D0%B5%D0%BD%D0%BD%D1%8B%D0%B9_%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82">drug</ext-link> belonging to the group of cationic <ext-link ext-link-type="uri" xlink:href="https://ru.wikipedia.org/wiki/%D0%90%D0%BD%D1%82%D0%B8%D1%81%D0%B5%D0%BF%D1%82%D0%B8%D0%BA%D0%B8">antiseptics</ext-link>, which is also a quaternary ammonium compound reported to have a wide array of biological activities including antiviral against HIV (<xref ref-type="bibr" rid="CR23">23</xref>). Miramistin is approved as broad-spectrum anti-infective agent in Russia (<xref ref-type="bibr" rid="CR24">24</xref>), but it does not appear to have been adopted in the rest of the world. There are numerous FDA approved drugs that have a quaternary nitrogen, and it is possible these could also have a similar broad antiseptic effect.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Quaternary ammonium compounds with known coronavirus activity</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Molecule</th><th>Antiviral activity</th><th>Mechanism</th><th>FDA approved</th><th>Uses</th></tr></thead><tbody><tr><td>Ammonium Chloride</td><td>Murine coronavirus, hepatitis C,</td><td>Lysosomotropic</td><td>Yes</td><td>Various uses including metabolic acidosis.</td></tr><tr><td>Cetylpyridinium chloride</td><td>Influenza, hepatitis B, poliovirus 1</td><td>Targets capsid and is lysosomotropic</td><td>Yes, GRAS</td><td>Antiseptic, mouthwash, cough lozenges, personal care products, cleaning agents etc.</td></tr><tr><td>Miramistin</td><td>HIV, influenza, herpes, SARS</td><td>Immunostimulating, targets capsid and is lysosomotropic</td><td>No, but is approved in Russia</td><td>Antiseptic</td></tr></tbody></table></table-wrap></p><p id="Par6">The current COVID-19 pandemic is sweeping the globe at an unprecedented rate fanned by our global connectivity. To date it has spurred drug discovery activity (albeit considerably impacted by research laboratory shutdowns) and much interest in drug repurposing in the hope of delivering effective drugs to the patient faster. The success of this approach will take time to validate as we await clinical trial data from all of the earliest compounds in the clinic. We hypothesized that text mining of the available published literature in PubMed would enable us to identify compounds faster that have been tested against other coronaviruses, but which were not currently being evaluated clinically. Our studies guided by this approach suggest that while many drugs have been tested, the lysosomotropic agent ammonium chloride and quaternary ammonium compounds such as cetylpyridinium chloride and miramistin may produce the desired antiviral effect but have not as yet been tested against SARS-CoV-2 <italic>in vitro</italic> or in clinical trials. We have briefly described this data mining process that identified these classes of compounds of interest and provide our analysis for others to expand up on (Supplementary Material, Table S<xref rid="MOESM1" ref-type="media">1</xref>). Limitations of the text mining approach are that at the time of writing there had only been reports of approximately 450 molecules associated with other coronaviruses and many of these could likely be discounted due to no reported antiviral activity, toxicity and perhaps most important, the lack of FDA approved status.</p></sec></sec><sec id="Sec4"><title>Summary</title><p id="Par7">We propose that in particular, cetylpyridinium chloride is a simple molecule that is cheap, safe, clinically approved, widely accessible in hospitals and the consumer sector and which could enter clinical trials immediately. If reported to have activity <italic>in vitro</italic> against SARS-CoV-2 subsequent delivery in the form of a mouthwash or nasal spray containing this compound may be an effective way both to combat the virus at its point of entry and reduce SARS-CoV-2 transmission. Similarly, this compound could be added to shampoo and body cleansers so that one could effectively bathe in low concentrations of this compound to destroy shed coronavirus. Cetylpyridinium chloride and many other quaternary ammonium compounds have already demonstrated their antiviral activity against a wide array of related coronaviruses as disinfectants and antiseptics, therefore they represent especially low hanging fruit for testing in humans. Due to their reported mechanisms they may also have much broader activity against viruses which could be useful to&#x000a0;address future enveloped viruses. Certainly, additional studies may be warranted to assess potential drug-drug or drug-transporter interactions. This work may also point to other related compounds that could be utilized, or at least enable the generation of new antiviral compounds that leverage the quaternary ammonium substructural fragment as a potential warhead. As simple as it sounds, it is entirely possible that we should be looking in our bathroom cupboards, for potential remedies against COVID-19.</p></sec><sec sec-type="supplementary-material"><title>Electronic supplementary material</title><sec id="Sec5"><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="11095_2020_2842_MOESM1_ESM.docx"><label>ESM 1</label><caption><p>(DOCX 47&#x000a0;kb)</p></caption></media></supplementary-material>
</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS AND DISCLOSURES</title><p>This work has been reviewed at the US EPA and has been approved for publication. The views expressed in this publication are those of the authors and do not necessarily represent the views or policies of the United States Environment Protection Agency. Reference to commercial products or services does not constitute endorsement.</p></ack><notes notes-type="funding-information"><title>Funding</title><p>We kindly acknowledge NIH funding: R44GM122196-02A1 from NIGMS, R21TR001718 from NCATS and R43AT010585-01S1 from NCCAM (PI &#x02013; Sean Ekins) and 1OT2TR002514&#x02013;01 (Pi &#x02013; Alexander Tropsha).</p></notes><notes><title>Compliance with Ethical Standards</title><notes id="FPar2" notes-type="COI-statement"><title>Conflict of Interest</title><p id="Par9">SE is CEO and owner of Collaborations Pharmaceuticals. All other co-authors have no conflicts of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gates</surname><given-names>B</given-names></name></person-group><article-title>Responding to Covid-19 - a once-in-a-century pandemic?</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><fpage>1677</fpage><lpage>1679</lpage><pub-id pub-id-type="doi">10.1056/NEJMp2003762</pub-id><pub-id pub-id-type="pmid">32109012</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Ekins S, Mottin M, Ramos PRPS, Sousa BKP, Neves BJ, Foil DH, Zorn KM, Braga RC, Coffee M, Southan C, Puhl AC, Andrade CH. D&#x000e9;j&#x000e0; vu: Stimulating Open Drug Discovery for SARS-CoV-2. Drug Discov Today. 2020; Apr 19:S1359-6446(20)30145-8. 10.1016/j.drudis.2020.03.019.</mixed-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stebbing</surname><given-names>J</given-names></name><name><surname>Phelan</surname><given-names>A</given-names></name><name><surname>Griffin</surname><given-names>I</given-names></name><name><surname>Tucker</surname><given-names>C</given-names></name><name><surname>Oechsle</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name></person-group><article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>20</volume><issue>4</issue><fpage>400</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30132-8</pub-id><pub-id pub-id-type="pmid">32113509</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Jeon S, Ko M, Lee J, Choi I, Byun SY, Park S, Shum D, Kim S. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.03.20.999730v1">https://www.biorxiv.org/content/10.1101/2020.03.20.999730v1</ext-link>.</mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, Zhang B, Li X, Zhang L, Peng C, Duan Y, Yu J, Wang L, Yang K, liu F, Jiang R, Yang X, You T, Liu X, Yang X, Bai F, Liu H, Liu X, Guddat LW, Xu W, Xiao G, Qin C, Shi Z, Jiang HY, Rao Z, yang H. Structure of Mpro from 1 COVID-19 virus and discovery of its inhibitors. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.02.26.964882v2">https://www.biorxiv.org/content/10.1101/2020.02.26.964882v2</ext-link>.</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>M</given-names></name></person-group><article-title>Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro</article-title><source>Cell Discov</source><year>2020</year><volume>6</volume><fpage>16</fpage><pub-id pub-id-type="doi">10.1038/s41421-020-0156-0</pub-id><pub-id pub-id-type="pmid">32194981</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Cao</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>M</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>W</given-names></name><name><surname>Xiao</surname><given-names>G</given-names></name></person-group><article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title><source>Cell Res</source><year>2020</year><volume>30</volume><issue>3</issue><fpage>269</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1038/s41422-020-0282-0</pub-id><pub-id pub-id-type="pmid">32020029</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="other">Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Burgstaller-Muehlbacher S, Pache L, De Jesus PP, Hull MV, Chang M, Chan JF-W, Cao J, Poon VK-M, Herbert K, Nguyen T-T, Pu Y, Nguyen C, Rubanov A, Martinez-Sobrido L, Liu W-C, Miorin L, White KM, Johnson JR, Benner C, Sun R, Schultz PG, Su A, Garcia-Sastre A, Chatterjee AK, Yuen K-Y, Chanda SK. A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals. bioRxiv. 2020:2020.2004.2016.044016.</mixed-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Wilde</surname><given-names>AH</given-names></name><name><surname>Jochmans</surname><given-names>D</given-names></name><name><surname>Posthuma</surname><given-names>CC</given-names></name><name><surname>Zevenhoven-Dobbe</surname><given-names>JC</given-names></name><name><surname>van Nieuwkoop</surname><given-names>S</given-names></name><name><surname>Bestebroer</surname><given-names>TM</given-names></name><name><surname>van den Hoogen</surname><given-names>BG</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name><name><surname>Snijder</surname><given-names>EJ</given-names></name></person-group><article-title>Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>8</issue><fpage>4875</fpage><lpage>4884</lpage><pub-id pub-id-type="doi">10.1128/AAC.03011-14</pub-id><pub-id pub-id-type="pmid">24841269</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dyall</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>CM</given-names></name><name><surname>Hart</surname><given-names>BJ</given-names></name><name><surname>Venkataraman</surname><given-names>T</given-names></name><name><surname>Holbrook</surname><given-names>MR</given-names></name><name><surname>Kindrachuk</surname><given-names>J</given-names></name><name><surname>Johnson</surname><given-names>RF</given-names></name><name><surname>Olinger</surname><given-names>GG</given-names><suffix>Jr</suffix></name><name><surname>Jahrling</surname><given-names>PB</given-names></name><name><surname>Laidlaw</surname><given-names>M</given-names></name><name><surname>Johansen</surname><given-names>LM</given-names></name><name><surname>Lear-Rooney</surname><given-names>CM</given-names></name><name><surname>Glass</surname><given-names>PJ</given-names></name><name><surname>Hensley</surname><given-names>LE</given-names></name><name><surname>Frieman</surname><given-names>MB</given-names></name></person-group><article-title>Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection</article-title><source>Antimicrob Agents Chemother</source><year>2014</year><volume>58</volume><issue>8</issue><fpage>4885</fpage><lpage>4893</lpage><pub-id pub-id-type="doi">10.1128/AAC.03036-14</pub-id><pub-id pub-id-type="pmid">24841273</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>NC</given-names></name><name><surname>Ekins</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>AJ</given-names></name><name><surname>Tropsha</surname><given-names>A</given-names></name></person-group><article-title>A bibliometric review of drug repurposing</article-title><source>Drug Discov Today</source><year>2018</year><volume>23</volume><issue>3</issue><fpage>661</fpage><lpage>672</lpage><pub-id pub-id-type="doi">10.1016/j.drudis.2018.01.018</pub-id><pub-id pub-id-type="pmid">29330123</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borba</surname><given-names>Mayla Gabriela Silva</given-names></name><name><surname>Val</surname><given-names>Fernando Fonseca Almeida</given-names></name><name><surname>Sampaio</surname><given-names>Vanderson Souza</given-names></name><name><surname>Alexandre</surname><given-names>Marcia Almeida Ara&#x000fa;jo</given-names></name><name><surname>Melo</surname><given-names>Gisely Cardoso</given-names></name><name><surname>Brito</surname><given-names>Marcelo</given-names></name><name><surname>Mour&#x000e3;o</surname><given-names>Maria Paula Gomes</given-names></name><name><surname>Brito-Sousa</surname><given-names>Jos&#x000e9; Diego</given-names></name><name><surname>Ba&#x000ed;a-da-Silva</surname><given-names>Djane</given-names></name><name><surname>Guerra</surname><given-names>Marcus Vinitius Farias</given-names></name><name><surname>Hajjar</surname><given-names>Ludhmila Abrah&#x000e3;o</given-names></name><name><surname>Pinto</surname><given-names>Rosemary Costa</given-names></name><name><surname>Balieiro</surname><given-names>Antonio Alcirley Silva</given-names></name><name><surname>Pacheco</surname><given-names>Ant&#x000f4;nio Guilherme Fonseca</given-names></name><name><surname>Santos</surname><given-names>James Dean Oliveira</given-names></name><name><surname>Naveca</surname><given-names>Felipe Gomes</given-names></name><name><surname>Xavier</surname><given-names>Mariana Sim&#x000e3;o</given-names></name><name><surname>Siqueira</surname><given-names>Andr&#x000e9; Machado</given-names></name><name><surname>Schwarzbold</surname><given-names>Alexandre</given-names></name><name><surname>Croda</surname><given-names>J&#x000fa;lio</given-names></name><name><surname>Nogueira</surname><given-names>Maur&#x000ed;cio Lacerda</given-names></name><name><surname>Romero</surname><given-names>Gustavo Adolfo Sierra</given-names></name><name><surname>Bassat</surname><given-names>Quique</given-names></name><name><surname>Fontes</surname><given-names>Cor Jesus</given-names></name><name><surname>Albuquerque</surname><given-names>Bernardino Cl&#x000e1;udio</given-names></name><name><surname>Daniel-Ribeiro</surname><given-names>Cl&#x000e1;udio-Tadeu</given-names></name><name><surname>Monteiro</surname><given-names>Wuelton Marcelo</given-names></name><name><surname>Lacerda</surname><given-names>Marcus Vin&#x000ed;cius Guimar&#x000e3;es</given-names></name></person-group><article-title>Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection</article-title><source>JAMA Network Open</source><year>2020</year><volume>3</volume><issue>4</issue><fpage>e208857</fpage><pub-id pub-id-type="doi">10.1001/jamanetworkopen.2020.8857</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizzen</surname><given-names>L</given-names></name><name><surname>Hilton</surname><given-names>A</given-names></name><name><surname>Cheley</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>R</given-names></name></person-group><article-title>Attenuation of murine coronavirus infection by ammonium chloride</article-title><source>Virology.</source><year>1985</year><volume>142</volume><issue>2</issue><fpage>378</fpage><lpage>388</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(85)90345-9</pub-id><pub-id pub-id-type="pmid">2997991</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="other">Hoffmann MM, Kleine-Weber H, Kruger N, Muller M, Drosten C, Pohlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor 2 ACE2 and the cellular protease TMPRSS2 for entry into target cells. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1.full.pdf">https://www.biorxiv.org/content/10.1101/2020.01.31.929042v1.full.pdf</ext-link>.</mixed-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashfaq</surname><given-names>UA</given-names></name><name><surname>Javed</surname><given-names>T</given-names></name><name><surname>Rehman</surname><given-names>S</given-names></name><name><surname>Nawaz</surname><given-names>Z</given-names></name><name><surname>Riazuddin</surname><given-names>S</given-names></name></person-group><article-title>Lysosomotropic agents as HCV entry inhibitors</article-title><source>Virol J</source><year>2011</year><volume>8</volume><fpage>163</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-163</pub-id><pub-id pub-id-type="pmid">21481279</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rabenau</surname><given-names>HF</given-names></name><name><surname>Kampf</surname><given-names>G</given-names></name><name><surname>Cinatl</surname><given-names>J</given-names></name><name><surname>Doerr</surname><given-names>HW</given-names></name></person-group><article-title>Efficacy of various disinfectants against SARS coronavirus</article-title><source>J Hosp Infect</source><year>2005</year><volume>61</volume><issue>2</issue><fpage>107</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1016/j.jhin.2004.12.023</pub-id><pub-id pub-id-type="pmid">15923059</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dellanno</surname><given-names>C</given-names></name><name><surname>Vega</surname><given-names>Q</given-names></name><name><surname>Boesenberg</surname><given-names>D</given-names></name></person-group><article-title>The antiviral action of common household disinfectants and antiseptics against murine hepatitis virus, a potential surrogate for SARS coronavirus</article-title><source>Am J Infect Control</source><year>2009</year><volume>37</volume><issue>8</issue><fpage>649</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1016/j.ajic.2009.03.012</pub-id><pub-id pub-id-type="pmid">19692148</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">Anon. Disinfectant Concentrations and Contact Times for EPA's List of Products Effective against Novel Coronavirus SARS-CoV-2, the Cause of COVID-19. 2020 1 April. Available from: <ext-link ext-link-type="uri" xlink:href="https://www.ecri.org/components/HDJournal/Pages/Disinfectant-Concentrations-for-EPA-list-N-COVID-19.aspx?tab=2">https://www.ecri.org/components/HDJournal/Pages/Disinfectant-Concentrations-for-EPA-list-N-COVID-19.aspx?tab=2</ext-link>.</mixed-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>DM</given-names></name><name><surname>Evans</surname><given-names>RK</given-names></name></person-group><article-title>Molecular mechanism and thermodynamics study of plasmid DNA and cationic surfactants interactions</article-title><source>Langmuir.</source><year>2006</year><volume>22</volume><issue>8</issue><fpage>3735</fpage><lpage>3743</lpage><pub-id pub-id-type="doi">10.1021/la052161s</pub-id><pub-id pub-id-type="pmid">16584250</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fromm-Dornieden</surname><given-names>C</given-names></name><name><surname>Rembe</surname><given-names>JD</given-names></name><name><surname>Schafer</surname><given-names>N</given-names></name><name><surname>Bohm</surname><given-names>J</given-names></name><name><surname>Stuermer</surname><given-names>EK</given-names></name></person-group><article-title>Cetylpyridinium chloride and miramistin as antiseptic substances in chronic wound management - prospects and limitations</article-title><source>J Med Microbiol</source><year>2015</year><volume>64</volume><issue>Pt 4</issue><fpage>407</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.000034</pub-id><pub-id pub-id-type="pmid">25681322</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mukherjee</surname><given-names>PK</given-names></name><name><surname>Esper</surname><given-names>F</given-names></name><name><surname>Buchheit</surname><given-names>K</given-names></name><name><surname>Arters</surname><given-names>K</given-names></name><name><surname>Adkins</surname><given-names>I</given-names></name><name><surname>Ghannoum</surname><given-names>MA</given-names></name><name><surname>Salata</surname><given-names>RA</given-names></name></person-group><article-title>Randomized, double-blind, placebo-controlled clinical trial to assess the safety and effectiveness of a novel dual-action oral topical formulation against upper respiratory infections</article-title><source>BMC Infect Dis</source><year>2017</year><volume>17</volume><issue>1</issue><fpage>74</fpage><pub-id pub-id-type="doi">10.1186/s12879-016-2177-8</pub-id><pub-id pub-id-type="pmid">28088167</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simmons</surname><given-names>G</given-names></name><name><surname>Gosalia</surname><given-names>DN</given-names></name><name><surname>Rennekamp</surname><given-names>AJ</given-names></name><name><surname>Reeves</surname><given-names>JD</given-names></name><name><surname>Diamond</surname><given-names>SL</given-names></name><name><surname>Bates</surname><given-names>P</given-names></name></person-group><article-title>Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry</article-title><source>Proc Natl Acad Sci U S A</source><year>2005</year><volume>102</volume><issue>33</issue><fpage>11876</fpage><lpage>11881</lpage><pub-id pub-id-type="doi">10.1073/pnas.0505577102</pub-id><pub-id pub-id-type="pmid">16081529</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krivorutchenko Iu</surname><given-names>L</given-names></name></person-group><article-title>KrivosheinIuS, Marennikova SS, Stepanova LG, Nosik DN, Kalnina LB, Rud'ko AP. [study of the anti-HIV activity of miramistin]</article-title><source>Vopr Virusol</source><year>1994</year><volume>39</volume><issue>6</issue><fpage>267</fpage><lpage>269</lpage><?supplied-pmid 7716921?><pub-id pub-id-type="pmid">7716921</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agafonov</surname><given-names>AP</given-names></name><name><surname>Skarnovich</surname><given-names>MO</given-names></name><name><surname>Petrishchenko</surname><given-names>VA</given-names></name><name><surname>Shishkina</surname><given-names>LN</given-names></name><name><surname>Sergeev</surname><given-names>AN</given-names></name><name><surname>Svistov</surname><given-names>VV</given-names></name><name><surname>Smirnov</surname><given-names>IV</given-names></name><name><surname>Kirichenko</surname><given-names>NA</given-names></name><name><surname>Krivoshein</surname><given-names>IS</given-names></name></person-group><article-title>In vitro study of antiviral activity of Myramistin against subtypes H3N2 and H5N1 of influenza virus</article-title><source>Antibiot Khimioter</source><year>2005</year><volume>50</volume><issue>12</issue><fpage>9</fpage><lpage>11</lpage><?supplied-pmid 19140480?><pub-id pub-id-type="pmid">19140480</pub-id></element-citation></ref></ref-list></back></article>